Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UQK1
UPID:
PPR3C_HUMAN
Alternative names:
Protein phosphatase 1 regulatory subunit 5; Protein targeting to glycogen
Alternative UPACC:
Q9UQK1; B2R7X0; O95686
Background:
Protein phosphatase 1 regulatory subunit 3C, also known as Protein phosphatase 1 regulatory subunit 5 and Protein targeting to glycogen, plays a pivotal role in glycogen metabolism. It acts as a glycogen-targeting subunit for PP1, regulating its activity by activating glycogen synthase, reducing glycogen phosphorylase activity, and limiting glycogen breakdown. This protein significantly enhances basal and insulin-stimulated glycogen synthesis across various cell types upon overexpression.
Therapeutic significance:
Understanding the role of Protein phosphatase 1 regulatory subunit 3C could open doors to potential therapeutic strategies.